Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture
Open Access
- 1 March 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 1307-1317
Abstract
Introduction: Leishmaniasis is a collective term used to describe various pathological conditions caused by an obligate intracellular protozoan of the genus Leishmania. It is one of the neglected diseases and has been given minimal attention by drug discovery and development stakeholders to narrow the safety and efficacy gaps of the drugs currently used to treat leishmaniasis. The challenge is further exacerbated by the emergence of drug resistance by the parasites. Methods: Aiming to look for potential anti-leishmanial hits and leads, we screened Medicines for Malaria Venture (MMV) Pathogen Box compounds against clinically isolated Leishmania donovani strain. In this medium-throughput primary screening assay, the compounds were screened against promastigotes, and then against amastigote stages. Results: From the total 400 compounds screened, 35 compounds showed > 50% inhibitory activity on promastigotes in the initial screen (1 μM). Out of these compounds, nine showed > 70% inhibition, with median inhibitory concentration (IC 50) ranging from 12 to 491 nM using the anti-promastigote assay, and from 53 to 704 nM using the intracellular amastigote assay. Identified compounds demonstrated acceptable safety profiles on THP-1 cell lines and sheep red blood cells, and had appropriate physicochemical properties suitable for further drug development. Two compounds (MMV690102 and MMV688262) were identified as leads. The anti-tubercular agent MMV688262 (delamanid) showed a synergistic effect with amphotericin B, indicating the prospect of using this compound for combination therapy. Conclusion: The current study indicates the presence of additional hits which may hold promise as starting points for anti-leishmanial drug discovery and in-depth structure–activity relationship studies.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral LeishmaniasisAntimicrobial Agents and Chemotherapy, 2013
- Substrate specificity of the deazaflavin‐dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazolesThe FEBS Journal, 2011
- A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific HitPLOS Neglected Tropical Diseases, 2011
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Small-Molecule Inhibitors of NADPH Oxidase 4Journal of Medicinal Chemistry, 2010
- Cutaneous and mucocutaneous leishmaniasisDermatologic Therapy, 2009
- Reproductive Biology and Breeding System of Aconitum balfourii (Benth) Muk: A High Altitude Endangered Medicinal Plant of Garhwal Himalaya, IndiaResearch Journal of Medicinal Plant, 2009
- The Isolation and Characterization of Murine MacrophagesCurrent Protocols in Immunology, 2008
- Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivativeBioorganic & Medicinal Chemistry Letters, 2006
- Drug Resistance in LeishmaniasisClinical Microbiology Reviews, 2006